New CAR t therapy targets Hard-to-Treat gut cancers

NCT ID NCT06055439

First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 17 times

Summary

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (CDH17). The goal is to see if it is safe and effective in shrinking tumors or controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

Conditions

Explore the condition pages connected to this study.